A new species of &lt;I&gt;Engleromyces&lt;/I&gt; from China, a second species in the genus

Whalley, M. A.; Khalil, Ahmed M. A.; Wei, T. Z.; Yao, Y. J.; Whalley, A.J.S.

doi:10.5248/112.317-

Cited by 7 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chinese collections, originally identified as E. goetzei, were later found to represent a second species, E. sinensis M.A. Whalley et al (Whalley et al 2010). Engleromyces produces cytochalasin D and 19, 20-epoxycytochalasin and a novel metabolite in E. sinensis, neoengleromycin, which is used for cancer treatments (Pedersen et al 1980;Liu et al 2002).…”

Section: Fungal Diversitymentioning

confidence: 98%

See 1 more Smart Citation

Towards a natural classification and backbone tree for Sordariomycetes

et al. 2015

View full text Add to dashboard Cite

Sordariomycetes is one of the largest classes of Ascomycota and is characterised by perithecial ascomata and inoperculate unitunicate asci. The class includes many important plant pathogens, as well as endophytes, saprobes, epiphytes, and fungicolous, lichenized or lichenicolous taxa. The class includes freshwater, marine and terrestrial taxa and has a worldwide distribution. This paper provides an updated outline of the Sordariomycetes and a backbone tree incorporating asexual and sexual genera in the class. Based on phylogeny and morphology we introduced three subclasses; D i a p o r t h o m y c e t i d a e , L u l w o r t h i o m y c e t i d a e a n dTogniniales. The outline is based on literature to the end of 2014 and the backbone tree published in this paper. Notes for 397 taxa with information, such as new family and genera novelties, novel molecular data published since the Outline of Ascomycota 2009, and new links between sexual and asexual genera and thus synonymies, are provided. The Sordariomycetes now comprises six subclasses, 28 orders, 90 families and 1344 genera. In addition a list of 829 genera with uncertain placement in Sordariomycetes is also provided.

show abstract

Section: Fungal Diversitymentioning

confidence: 98%

“…28 (3): 327 (1900) Engleromyces (Xylariaceae) was introduced by Hennings (1900) for a single species, E. goetzei Henn. ; the genus is characterized by massive, hard stromata (Whalley et al 2010). Chinese collections, originally identified as E. goetzei, were later found to represent a second species, E. sinensis M.A.…”

Section: Fungal Diversitymentioning

confidence: 99%

Towards a natural classification and backbone tree for Sordariomycetes

et al. 2015

View full text Add to dashboard Cite

show abstract

“…It was described by German mycologist Paul Christoph Hennings in 1980 [2]. Engleromyces contains two species, and which were found in the regions of Tibet, Yunnan province of China, and Kenya highlands [3]. As a traditional African medicine, E. goetzei is a reputed medicine against pneumonia, colds, fever, malaria-related headache as well as liver diseases and abdominal pains [4].…”

Section: Introductionmentioning

confidence: 99%

Antiproliferative and Enzyme Docking Analysis of Engleromycin from Engleromyces goetzei

Zhang

Chen

et al. 2019

Molecules

View full text Add to dashboard Cite

Engleromyces goetzei P. Henn. (E. goetzei) has been widely used as a traditional herb for many years in Kenya due to its diverse biological effects. Although engleromycin was first isolated from E. goetzei in 1980, its pharmacological activity is still unknown. In this study, engleromycin from E. goetzei was identified by spectroscopic analyses, and subsequently examined for its antiproliferative activity using human cancer cell lines of SGC-7901, HT-29, HeLa and A549. As a result, it was revealed that engleromycin strongly inhibited the growth of SGC-7901, HT-29, HeLa and A549 cells with IC50 values at 26.77 ± 1.69 µM, 7.73 ± 0.18 µM, 7.00 ± 0.12 µM and 3.14 ± 0.03 µM, respectively. The results of topoisomerase II (Top II) inhibition assay in vitro implied that engleromycin might be a Top II inhibitor. Further insights into the potential mechanism of antiproliferative activity displayed that engleromycin could dock into the binding pockets of Top II, like the clinical inhibitor doxorubicin, and then inhibit the biological activity of Top II. Taken together, our findings suggest that engleromycin has an anticancer potential, and may serve as a leading compound for the development of antitumor agents.

show abstract